Does Raising the Cofactor Actually Change Cellular Energy Output? NMN, NR and the Precursor Question

TL;DR

• NAD⁺ is a shuttle, not a fuel - in a healthy, well-fed cell, cofactor availability is rarely the step limiting ATP output.
• **The 2026 Nature Metabolism head-to-head** in 65 adults found NR and NMN both roughly doubled whole-blood NAD⁺, with no meaningful difference between them.
• **A six-person iScience crossover disagreed**, putting NR ahead at matched intake - small, short, and promoted by an NR manufacturer.
• The decline is tissue-specific, not universal - "halved by 40" is a marketing extrapolation from one skin study, and turnover can hold even where concentration falls.
• Every blood NAD⁺ number here carries a standing caveat - a separate Nature Metabolism paper (14 May 2026, seven cohorts) found whole-blood NAD⁺ stable across age yet responsive to NR, which makes it a poor marker of ageing and a usable marker of supplementation.
• NMN is a lawful dietary ingredient in the US again - the FDA reversed its 2022 exclusion across late 2025, which settles status, not efficacy.
• The homocysteine worry belongs to nicotinamide, not the precursors - the acute eightfold rise appeared with NAM, while NR and NMN did not significantly raise it.

The supplement aisle argues about which precursor is better. The prior question - whether raising the cofactor changes how much ATP your mitochondria produce - barely gets asked.

Updated September 2026: adds the blood-versus-tissue caveat as a standing qualifier on every blood-NAD⁺ number in this article, citing the 14 May 2026 seven-cohort Nature Metabolism paper: blood NAD⁺ responds to NR but not to age, making it a poor ageing marker and a usable supplementation marker.

Updated September 2026: adds NMN's US regulatory status - the FDA's 2022 exclusion of NMN from the dietary supplement definition was reversed across late 2025, and NMN is treated as a lawful dietary ingredient as of mid-2026. This is a status change, not an efficacy finding; the evidence assessment is unchanged.

Updated August 2026: re-cut around cellular energy production rather than precursor branding. The full NMN-vs-NR comparison is retained below, where it belongs - downstream of the question that actually matters.

Evidence-tiered; primary literature only. Educational content, not medical advice or a treatment claim. No doses, protocols, or supplement regimens are given; those are a physician determination. NMN and NR are sold as supplements; neither is an approved therapy for aging or any disease.

---

If you've spent any time in the longevity aisle, you've met the argument: NMN vs NR, two camps, each insisting the other is wasting your money. It's one of the most heated debates in the supplement world - and one of the least useful, because it skips the two questions that decide whether any of it matters. What is the cofactor actually doing in energy production? And if you raise it, does the cell produce more ATP?

Here's the short version, and then the honest detail. NAD⁺ genuinely matters - it is the electron carrier without which oxidative phosphorylation stops. It does appear to decline with age in some tissues, though by less than the headlines claim. NMN and NR are both precursors - raw materials your body builds NAD⁺ from - and the best current human data suggest they raise blood NAD⁺ to a broadly similar extent, which makes the tribal war more marketing than biology. The interesting story isn't which precursor wins. It's how little of any of them reliably reaches mitochondria, and why raising a cofactor that wasn't the bottleneck doesn't reliably raise energy output.

What the cofactor actually does in energy production

NAD⁺ (nicotinamide adenine dinucleotide) is a coenzyme - it doesn't act alone, it enables other enzymes to do their jobs. It has three roles worth knowing:

• Electron transport. NAD⁺ accepts electrons stripped from fuel during glycolysis and the TCA cycle, becoming NADH, and delivers them to the electron transport chain in the inner mitochondrial membrane. The chain uses that energy to pump protons across the membrane; protons flowing back through ATP synthase are what physically drive ATP production. Without the carrier, the line stops. This is the role everyone knows.
• Repair. A family of enzymes called PARPs uses NAD⁺ to repair DNA, which breaks routinely from oxidative stress and normal replication. Every repair spends NAD⁺ - genuinely consuming it, unlike the electron shuttle, which is recycled.
• Regulation. The sirtuins - a family of "housekeeping" proteins that influence inflammation, metabolism, stress response, and which genes are switched on - are NAD⁺-dependent, and also consume it.

So the cofactor sits at the intersection of energy, repair, and cellular regulation. That triple role is exactly why people get excited about it - and why low levels are theorized to matter.

The step the marketing skips: a shuttle is not a fuel

NAD⁺ carries electrons; it isn't burned for energy itself. It cycles between NAD⁺ and NADH continuously, and the pool is small relative to the traffic moving through it. Which raises the obvious question: is that pool ever the thing limiting ATP output?

In a healthy, well-fed cell, generally not. ATP production is more usually constrained by demand itself, by substrate and oxygen delivery, by the capacity and integrity of the electron transport chain complexes, and by how many functioning mitochondria the cell has. A production line runs at the speed of its slowest step, and cofactor availability is rarely that step. This is why exercise - which increases mitochondrial number and quality - produces changes in energy capacity that no precursor has demonstrated.

The plausible exceptions are cells where the pool genuinely is depleted: specific tissues, specific disease states, severe metabolic stress. That is a much narrower claim than the one on the label, and it's the reason the whole field has drifted toward measuring first. We take that argument up in mitochondrial support without the maximalism.

The honest correction on decline. You'll often hear "your NAD⁺ is halved by 40." That figure is overstated. The frequently-cited human study (Massudi and colleagues, PLoS One, 2012) measured skin and found NAD⁺ negatively correlated with age - real, but it's one tissue, and the "50% by 40" gloss is a marketing extrapolation, not the paper's claim. Lower NAD⁺ with age has since been documented in skeletal muscle and brain too, but a 2021 review in Nutrients re-examined the whole literature and concluded the evidence for a universal, global decline is thinner and more tissue-specific than commonly stated. There's also a crucial distinction the supplement pitch ignores: concentration is not the same as flux. One mouse study (McReynolds and colleagues, Cell Systems, 2021) found NAD⁺ turnover was maintained in aged tissue even where the standing concentration was lower - the pool can be smaller while still cycling briskly, which for a shuttle is what actually counts. The full evidence picture is in cellular energy and age.

The standing caveat on every blood number in this article: blood is not tissue. A separate Nature Metabolism paper published 14 May 2026 (volume 8, pages 1282–1290) pooled seven independent human cohorts, more than 300 individuals, and measured whole-blood NAD⁺ with a rigorously validated UHPLC–high-resolution mass spectrometry method. Whole-blood NAD⁺ was remarkably stable across age and stable across lifestyle interventions - but it did change in response to NR supplementation. The authors' conclusion is that this challenges the utility of blood NAD⁺ as a biomarker of ageing or of lifestyle factors.

Read that carefully, because it cuts both ways. It does not mean NAD⁺ fails to decline with age: direct measurements in skin, brain, skeletal muscle and liver still show age-related decline, and that finding stands. It means blood is a poor proxy for systemic NAD⁺ status - a measurement correction, not a refutation of the decline hypothesis. And there is a neat consequence for this article in particular: a number that moves with NR but not with age is exactly what makes blood NAD⁺ a poor ageing marker and a usable supplementation marker. So when the trials below report that a precursor "doubled blood NAD⁺," the defensible reading is that the compound got in and was converted - not that the tissue you care about was topped up, and not that you have corrected an age-related deficit. Both comparison trials in the next section measured blood. Keep that in view for all of them. The full argument is in cellular energy and age.

Why the cofactor pool drops: spending more, making less

To the extent NAD⁺ does fall with age, it's a two-sided budget problem.

On the spending side, the main culprit is an enzyme called CD38, which consumes NAD⁺ and rises with age-related inflammation (Camacho-Pereira and colleagues, Cell Metabolism, 2016). A big driver of that inflammation is senescent cells - cells that should have been cleared but linger and leak inflammatory signals; their secretions push immune cells to express more CD38, which burns through more NAD⁺ (Covarrubias and colleagues, Nature Metabolism, 2020). PARPs add to the bill: more DNA damage with age means more repair, and every repair costs NAD⁺.

On the making side, the body's NAD⁺ recycling (the salvage pathway, via the enzyme NAMPT) becomes less efficient with the same age-related stress and inflammation. So you're spending more and replacing it more slowly - the classic "expenses up, income down" squeeze.

This is the genuinely useful frame: the pool isn't lost to a leak you can simply plug. It's a balance between consumption and synthesis, and a precursor only addresses one side of that ledger.

NMN vs NR: the war that mostly isn't

Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors - partially-assembled NAD⁺. NMN is conventionally described as one step closer to NAD⁺; NR is a smaller molecule one step further back, which some argue helps it enter cells. For years each camp built a marketing story on those single-step differences.

What does the human data actually show when they're put side by side? Until 2026, no trial had directly compared them in the same study. Now two have - and they don't fully agree, which is itself the honest headline:

• A **2026 head-to-head trial in Nature Metabolism (65 healthy adults, parallel groups, two weeks) found NMN and NR raised whole-blood NAD⁺ to a comparable degree - both roughly doubling it - with no meaningful difference** between them. Plain nicotinamide (NAM) didn't produce the same sustained rise.
• A **smaller 2026 crossover study in iScience (Berven and colleagues, six adults) found the opposite emphasis: at matched intake, NR raised blood NAD⁺ appreciably more than NMN**.

How to read a conflict like that honestly: the larger, parallel-group trial points to "roughly equivalent," the small crossover points to "NR ahead." Neither is the final word - both are short, both are small by clinical standards, and one of them (the NR-favouring result) is most loudly promoted by an NR manufacturer, which is worth knowing. The defensible conclusion today is that at comparable intakes, NMN and NR both reliably raise blood NAD⁺, and any difference between them is modest and unsettled - not the chasm the marketing implies.

There's a more surprising finding buried in the larger trial that quietly undermines both marketing stories. It suggests NMN and NR may not be absorbed directly into circulation at all, but are first broken down - substantially by gut bacteria - into nicotinic acid (NA), which is what actually drives the blood-NAD⁺ rise. If that holds up, the whole "NMN is more direct, NR enters cells better" debate is arguing about a doorway neither compound walks through intact. The science here is still moving, but it's a good reminder of how much of the precursor marketing rests on tidy diagrams that the body doesn't honour.

NMN's legal status in the US changed - and a lot of writing on this topic hasn't noticed

One reason the NMN-vs-NR argument reads oddly in older articles is that for roughly three years the two compounds were not on the same regulatory footing, and a great deal of still-circulating content was written during that window.

In November 2022 the FDA took the position that NMN was excluded from the definition of a dietary supplement, on the basis that it had been authorised for investigation as a drug. NR was never subject to that exclusion. The practical effect was that NMN's status in the US market was contested for the next three years while NR's was not - and much of the "NMN is banned" and "NMN is being pulled" commentary dates from exactly this period.

That position has been reversed. Following a legal challenge from the Natural Products Association and a reconsideration that concluded across late 2025, the FDA issued letters confirming that it no longer excludes NMN from the dietary supplement definition - accepting evidence that NMN had been marketed as a supplement in the US before the drug-investigation authorisation, which triggers the statutory "race to market" provision. As of mid-2026, NMN is treated as a lawful dietary ingredient in the United States, and NMN and NR are on the same regulatory footing.

Three things follow, and the third is the one that matters most here:

• Anything you read asserting NMN is banned, excluded, or being withdrawn in the US is out of date. Check the date on the page.
• This resolves a status question, not a scientific one. The FDA's reconsideration turned on when NMN was first marketed - a question of commercial history and statutory sequence. It involved no assessment of whether NMN works, no efficacy review, and no safety approval.
• Lawful to sell is not the same as shown to work. Nothing in the preceding sections changes because of this. NMN remains a supplement, not an approved therapy for ageing or any disease, and the evidence summarised above - that precursors reliably raise blood NAD⁺, and that what this does for healthy people is much less established - is exactly where it was before the reversal.

Regulatory status elsewhere differs and moves independently; the position above is the US one.

Oral, injection, IV: what delivery actually changes

The other big debate is the route. The key fact that cuts through it: intact NAD⁺ is too large to enter your cells. Whether you swallow it, inject it, or run it through an IV, your body still has to break it down into smaller precursors, import those, and rebuild NAD⁺ inside the cell - and then, for energy purposes, get it into the mitochondrion. No route delivers ready-made cofactor straight to the electron transport chain.

• Oral precursors face the gut and then a mandatory first pass through the liver - a metabolically greedy organ that takes a large share of incoming building blocks for its own use before the rest reaches the body. (You'll hear a specific "the liver takes 70%" figure; treat that as illustrative, not a precise measured value.) This is part of why oral precursor intakes in trials are relatively large. Liposomal formulations claim to shield the cargo and improve delivery; that's mechanistically plausible and an area of active study, but real-world questions remain about whether the liposomes survive manufacturing and shelf life. Promising, not proven.
• Injection mainly buys you a bypass of the gut and that first-pass liver tax. It is not a different molecule and not magic - the same intracellular breakdown-and-rebuild still has to happen.
• IV NAD⁺ is the most aggressive and most expensive option, often pitched as a "rescue" when someone is genuinely depleted (e.g., after serious illness). It comes with well-known infusion-related reactions - flushing, chest tightness, nausea - that track with how fast it's given. Whether an IV is appropriate is a clinical decision, not a consumer one; and for most people the evidence does not support paying hundreds of dollars per infusion to maintain a cofactor pool that is probably not the constraint.

The practical point isn't "pick the strongest route." It's that route changes the logistics of getting precursors in - not the underlying biology of what the cell then has to do, and not whether the cell was short of cofactor to begin with.

The methylation question - and where the video gets it slightly wrong

A common warning: high intakes of NAD⁺ precursors deplete your methyl groups, because the body tags excess for excretion using methylation, which can drive up homocysteine (a cardiovascular-risk marker). That's why some people are told to take a methyl donor like TMG alongside.

The physiology is real, but the data add an important correction. In the 2026 Nature Metabolism head-to-head, the dramatic homocysteine spike (around an eightfold acute rise) showed up with plain nicotinamide (NAM) - not with NR or NMN, which did not significantly raise it. So the methylation-load concern is strongest for high-intake niacin/nicotinamide, and looks much weaker for the two precursors people are actually arguing about. We're not going to turn this into a "take X with Y" recipe - that's a physician's call against your own bloodwork - but the honest version is: the homocysteine worry has been somewhat over-generalised from NAM to all NAD⁺ precursors, and the head-to-head evidence doesn't support that leap.

The resveratrol myth

For about a decade the standard advice was to pair NAD⁺ precursors with resveratrol to "activate your sirtuins." The science has moved on, and not kindly. The original claim that resveratrol directly activates SIRT1 turned out to be an artifact of a flawed lab assay that used a fluorophore-tagged substrate; with native substrates, resveratrol does not directly activate the enzyme (Beher and colleagues, 2009; Pacholec and colleagues, Journal of Biological Chemistry, 2010). Later work suggested any real effect is indirect (e.g., via PDE4 inhibition; Park and colleagues, Cell, 2012) and at best substrate-specific. The bottom line: there is no good human evidence that adding resveratrol to a NAD⁺ precursor does anything for your "longevity genes." It persists in products mostly because the story is sticky, not because the data hold.

The honest limits (the part the marketing skips)

• Raising blood NAD⁺ is not the same as producing more ATP. The trials reliably show precursors increase circulating NAD⁺. What that does for healthy people - energy, healthspan, disease risk - is far less established, and no trial has demonstrated that a precursor increases ATP production in human tissue. The strongest specific human result is narrow: NMN improved muscle insulin sensitivity in prediabetic women (Yoshino and colleagues, Science, 2021) - a metabolic outcome, not an energy-output one. Most of the sweeping anti-aging claims remain extrapolation from mice.
• Blood ≠ tissue ≠ mitochondrion ≠ function. A rise you can measure in blood doesn't guarantee the tissues that matter got more, that the mitochondria inside them got more, or that anything downstream changed. And concentration isn't flux. The 14 May 2026 seven-cohort data sharpen this: blood NAD⁺ tracks NR intake but not age, so it is evidence that a precursor arrived - the narrow, real thing it can tell you - and not evidence of an age-related deficit corrected.
• Human outcome data is thin relative to the marketing. Biomarker movement is well documented. Clinical benefit in healthy adults is not. That gap is the single most important thing to hold onto.
• There are open safety questions, not just upside. A 2022 study (Maric and colleagues, Biosensors and Bioelectronics) found an NR-enriched diet increased brain metastases in an immunocompromised mouse model of aggressive triple-negative breast cancer. It's preclinical, in a deliberately aggressive/immune-deficient model, and other work disagrees - so it's a reason for measured caution and physician input, not panic, and certainly not "more is always better."
• "Energy in a bottle" is the wrong expectation. The cofactor is part of a maintenance system, not a stimulant. The honest framing from clinicians who study it: it's one way cells keep the lights on - and the foundations (sleep, exercise, managing stress, not being chronically inflamed) move both the cofactor economy and actual mitochondrial capacity more than any capsule.

The bigger point

The NMN-vs-NR war is a great example of how the supplement market manufactures a decision where the science doesn't really offer one - and, more importantly, manufactures it at the wrong level. At comparable intakes both raise blood NAD⁺; the differences are small and unsettled; the route mostly changes logistics, not biology; and the resveratrol add-on is a holdover from a debunked assay. None of that means the cofactor doesn't matter - mechanically, it plainly does. It means the useful question isn't "which precursor wins," it's "is cofactor supply what's limiting my cellular energy production in the first place, what's driving it, and what does my data support doing about it?"

That's a question answered with measurement and a clinician who'll read this evidence at its real weight - promising where it's promising, unproven where it's unproven - not with a louder marketing claim.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore NAD⁺.

Related reading

• Mitochondria and aging: why your cellular engines matter · Cellular energy and age: what happens to ATP production · SS-31 vs MOTS-c
• Mitochondrial support without the maximalism - the question that sits upstream of which precursor you choose
• GlyNAC and the glutathione axis - glutathione depletion and NAD⁺ depletion are different substrate problems, routinely conflated
• Part of Mitochondrial Function & Cellular Energy: The Complete Guide

---

Educational content. Not medical advice and not a treatment claim. NMN and NR are sold as dietary supplements and are not approved therapies for aging or any disease; IV NAD⁺ is administered in clinical settings and carries infusion-related risks. Conditions and outcomes named appear here as research context, not established indications. Any use is best decided with a physician, against individual bloodwork. For Malaysia-facing care, health and treatment claims are subject to MAB requirements.

Primary references

• Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative stress and NAD⁺ metabolism in human tissue. PLoS One. 2012;7(7):e42357.
• Human whole-blood NAD⁺ levels do not vary with age or lifestyle interventions. Nat Metab. Published 14 May 2026;8:1282–1290. (Seven independent human cohorts, more than 300 individuals; rigorously validated UHPLC–high-resolution mass spectrometry. Whole-blood NAD⁺ remarkably stable across age and across lifestyle interventions, but responsive to nicotinamide riboside supplementation. Authors conclude this challenges the utility of blood NAD⁺ as a biomarker of ageing or of lifestyle factors. Distinct from the Christen head-to-head trial below. Tissue-level decline in skin, brain, skeletal muscle and liver is unaffected by this result.)
• Whole-blood NAD⁺ levels do not reflect healthy ageing. Nat Metab. 2026. (Accompanying piece to the seven-cohort study above.)
• Age-Dependent Decline of NAD⁺ - Universal Truth or Confounded Consensus? (review). Nutrients. 2021;14(1):101.
• McReynolds MR, Chellappa K, Chiles E, et al. NAD⁺ flux is maintained in aged mice despite lower tissue concentrations. Cell Syst. 2021;12(12):1160–1172.
• Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127–1139.
• Covarrubias AJ, Kale A, Perrone R, et al. Senescent cells promote tissue NAD⁺ decline during ageing via the activation of CD38⁺ macrophages. Nat Metab. 2020;2:1265–1283.
• Trammell SAJ, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948.
• Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD⁺ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286.
• Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229.
• Berven H, Kverneng S, Sheard E, et al. The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation. iScience. 2026;29:114764. (Haukeland University Hospital / University of Bergen; crossover, n=6; NR raised blood NAD⁺ substantially more than NMN at matched intake.)
• Christen S, Cuénoud B, et al. Head-to-head comparison of NR, NMN and nicotinamide on whole-blood NAD⁺ in healthy adults. Nat Metab. 2026. (Nestlé Research, Lausanne; n=65, parallel; NR and NMN both ~doubled blood NAD⁺ with no significant difference; evidence for gut-microbiota conversion to nicotinic acid; NAM - not NR/NMN - drove an acute homocysteine rise.)
• Maric T, et al. A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD⁺ metabolism. Biosens Bioelectron. 2022. (Goun lab, University of Missouri; NR-enriched diet increased brain metastases in an immunocompromised triple-negative breast cancer mouse model - small, preclinical, and contested by other work.)
• Beher D, Wu J, Cumine S, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des. 2009;74(6):619–624.
• Pacholec M, Bleasdale JE, Chrunyk B, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 2010;285(11):8340–8351.
• Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148(3):421–433.